• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Mallon-De Castro Anna Christin

    11/12/25 8:50:47 AM ET
    $EMIS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EMIS alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Mallon-De Castro Anna Christin

    (Last) (First) (Middle)
    C/O EMMIS ACQUISITION CORP
    515 E LAS OLAS BLVD, SUITE 120

    (Street)
    FORT LAUDERDALE FL 33301

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    09/24/2025
    3. Issuer Name and Ticker or Trading Symbol
    Emmis Acquisition Corp. [ EMIS ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Anna C Mallon holds membership interests in Emmis Capital Sponsor LLC Sponsor LLC (the "Sponsor"), the sponsor of the Issuer. However, Anna C Mallon does not have voting rights over any securities held by the Sponsor and accordingly disclaims any beneficial interest other than to the extent of her pecuniary interest.
    No securities are beneficially owned.
    /s/ Anna C Mallon 11/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $EMIS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EMIS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EMIS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Emmis Acquisition Corp.

    SCHEDULE 13G - Emmis Acquisition Corp. (0002075816) (Subject)

    11/13/25 4:37:06 PM ET
    $EMIS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Emmis Acquisition Corp.

    10-Q - Emmis Acquisition Corp. (0002075816) (Filer)

    11/13/25 4:18:27 PM ET
    $EMIS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Emmis Acquisition Corp.

    SCHEDULE 13G - Emmis Acquisition Corp. (0002075816) (Subject)

    11/13/25 9:59:43 AM ET
    $EMIS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EMIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Mallon-De Castro Anna Christin

    3 - Emmis Acquisition Corp. (0002075816) (Issuer)

    11/12/25 8:50:47 AM ET
    $EMIS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EMIS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sichenzia Ross Ference Carmel LLP Achieves Firm Record Advising on Over 170 Transactions Totaling Over $14 Billion in 2025

    NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference Carmel LLP ("SRFC") reported that in 2025 it advised on over 170 announced transactions, with the total value of these transactions exceeding $14 billion, far surpassing the firm's strong performance in 2024. The transactions, on behalf of various market participants, such as issuers, underwriters and investors, included initial public offerings, secondary public offerings, registered direct offerings, private placements, mergers, acquisitions and cryptocurrency transactions. In October of 2025, for the fifth consecutive quarter, SRFC was ranked first in the nation for issuer counsel among securities law firms in Placement

    1/20/26 8:00:00 AM ET
    $EMIS
    $NCRA
    $SOUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Farming/Seeds/Milling
    Consumer Staples